期刊文献+

弥漫性大B细胞淋巴瘤组织MYC和Bcl-2及Bcl-6检测的预后价值 被引量:12

Prognosis judgment value of MYC,Bcl-2 and Bcl-6 detection in patients with diffuse large B cell lymphom
原文传递
导出
摘要 目的探讨检测MYC、Beb2和Bcl-6在弥漫性大B细胞淋巴瘤患者预后判断中的价值。方法回顾性分析郑州人民医院2007—06—01—2009—06一01确诊的159例弥漫性大B细胞淋巴瘤组织标本,间期荧光原位杂交方法检测MYC断裂、IGH/Bcl-2融合及Bcl-6基因断裂;免疫组织化学方法检测MYC、Bcb2及Bc卜6的表达丰度,并分析其与患者免疫学分型及预后的关系。结果国际预后指数(international prognosticindex,IPI)评分较高(IPI为3~5)的患者MYC表达高于IPI评分较低组(IPI为o~2),χ2=1.25;P=0.04;CD5+与生发中心B细胞样(germinal center B-cell-like,GCB)亚型患者的Bcl-2表达增高,χ2值分别为2.22和13.70,P值分别为0.001和0.002;Bcl-6的表达降低,χ2值分别为5.58和7.26,P值分别为0.004和0.007。MYC、Bcl-2低表达均使患者的总生存时间(overall survival,OS)和无进展生存期(progression-free survival,PFS)的风险比(hazard ratio,HR)增加,P值分别为0.005、0.016、0.003和0.001,Bcb6的高表达使患者的PFS的HR增加,P=0.035;IPI评分较低患者较评分较高患者的OS与PFS的HR增加,P值均为0.001。结论MYC、Bcl-2和Bel-6检测对弥漫性大B细胞淋巴瘤患者的预后具有判断价值,可作为判断顸后的分子标志物。 OBJECTIVE To investigate the prognosis judgment value of MYC/Bcl-2/ Bcl-6 detection in patients with diffuse large ]3 cell lymphoma. METHODS A retrospective analysis of 159 patients with diffuse large B cell lymphoma tissue specimens were conducted in Zhengzhou People's Fiospital from June 1,2007 to June 1,2009. FISH was used to detect the break of gene MYC and Bcl-6 and the fusion of IGH/Bcl-2, the expression levels of MYC, Bcl-6, Bcl-2 in the tumor tissue were detected by immunohistochemistry. The relationship of MYC/Bcl-2 break and the fusion of IGH/Bcl-2 with the prognosis of patients were analyzed. RESULTS The expression of MYC in low IPI group (IPI= 3--5) was higher than that of low IPI score group (IPI= 0-2;χ2= 1.25, P= 0.04). In CD5+ and GCB subgroup,the expression of Bcl-2 was increased (χ2=2.22,P=0.001;χ2=13. 70,P=0. 002) ,but the Bcl-6 was decreased (χ2=5. 58,P=0. 004; χ2=7.26,P=0. 007). Lower expression of MYC,Bcl-2 lead to a higher HR of OS and PFS (P values were 0. 005, 0. 016, 0. 003 and 0. 001), higher expression of Bcl-6 lead to a higher FIR of PFS (P= 0. 035). Low IPI score was also lead to high HR of PFS and OS than that of high IPI score (Both P values were 0. 001). CONCLUSION The expression of MYC,Bcl-2 and Bcl-6 can predict the prognosis of DLBCL,they can be used in the future as prognostic markers for patients with DLBCL.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2015年第15期1193-1197,共5页 Chinese Journal of Cancer Prevention and Treatment
关键词 弥漫性大B细胞淋巴瘤 MYC BCL-2 BCL-6 预后 diffuse large B cell lymphoma MYC Bcl-2 gcl-6 prognosis
  • 相关文献

参考文献25

  • 1Frederiksen BL, Dalton SO, Osier M, et al. Socioeconomic posi-tion ,treatment.and survival of non-Hodgkin lymphoma in Den-mark: A nationwide study [ J]. Br J Cancer, 2012, 106 ( 5 ):988-995.
  • 2Kearney BJ.To LB,Kearney DJ,et al. Outcomes of lymphoma inSouth Australia,1977 — 2007 [J], Med J Aust,2012, 196 ( 1 ):54-57.
  • 3Pulte D, Gondos A, Brenner H. Expected long-term survival ofolder patients diagnosed with non-Hodgkin lymphoma in 2008 —2012[J/CD]. Cancer Epidemiol.2012,36(1) :el9-25.
  • 4Boyle J,Beaven AW, Diehl LF,et al. Improving outcomes in ad-vanced DLBCL. Systemic approaches and radiotherapy[J], On-cology (Williston Park) ,2014,28(12) :1074-1081,1084.
  • 5Tina JE, Narayanaswamy M, Sundaresh KJ * et al. Primary ex-tranodal variant of non-Hodgkin, s lymphoma [ J], BMJ CaseRep,2014,doi: 10. 1136/bcr—2013 —010132.
  • 6van de Schans SA,Issa DE,Visser O*et al. Diverging trends inincidence and mortality,and improved survival of non-Hodgkin^lymphoma, in the Netherlands, 1989 — 2007 [J]. Ann Oncol,2012,23(1):171-182.
  • 7Sabattini E, Bacci F. Sagramoso C, et al. WHO classification oftumours of haematopoietic and lymphoid tissues in 2008 : an o-verview[J]. Pathologica,2010,102(3) :83-87.
  • 8de Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prog-nostic markers in diffuse large B-cell lymphoma: validation of tissuemicroarray as a prerequisite for broad clinical applications ( a studyfrom the Lunenburg Lymphoma Biomarker Consortium) [J]. J ClinPathol,2009,62(2) :128-138.
  • 9Tohda S. Overview of lymphoid neoplasms in the fourth editionof the WHO classification [ J]. Rinsho Byori, 2012,60 (6):560-564.
  • 10Iqbal J,Greiner TC,Patel K,et al. Distinctive patterns of BCL6molecular alterations and their functional consequences in differ-ent subgroups of diffuse large B-cell lymphoma[J]. Leukemia,2007,21(11):2332-2343.

二级参考文献19

  • 1许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 2Chen F,Castranova V,Shi X.New insights into the role of nuclear factor-kappaB in cell growth regulation[J].Am J Pathol,2001,159(2):387-397.
  • 3Hicklin D I,Ellis L M.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23(5):1011-1027.
  • 4Weidner N.Current pathologic methods for measuring intratumoral microvessle density within breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-173.
  • 5Factor V,Oliver AL,Panta GR,et al.Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice[J].Hepatology,2001,34 (1):32-41.
  • 6Takahashi M,Matsui A,Inao M,et al.ERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells[J].Hepatol Res,2003,26(3):232-236.
  • 7Li J,Zhang YP,Kirsner RS.Angiogenesis in wound repair:angiogenic growth factors and the extracellular matrix[J].Microsc Res Tech,2003,60(1):107-114.
  • 8Watanabe M,Dewan MZ,Okamura T,et al.A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo[J].Int J Cancer,2005,114(1):32-38.
  • 9Paik JH,Jang JY,Jeon YK. MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphorna[J].Clinical Cancer Research,2011,(14):4761-4771.
  • 10Zhu H,Wang Q,Hu C. High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy[J].Tumour Biology,2011,(06):1147-1153.

共引文献17

同被引文献90

  • 1蒋会勇,李慧灵,胡海,何滢,赵彤.弥漫性大B细胞淋巴瘤t(14;18)易位及bcl-2基因扩增的检测[J].中华病理学杂志,2007,36(2):84-89. 被引量:28
  • 2梁云,周韧,张焕兰,毛峥嵘.弥漫性大B细胞淋巴瘤中Bcl-2/IgH易位的初步研究[J].实用肿瘤杂志,2007,22(3):232-235. 被引量:2
  • 3李丽霞,郜艳晖,张丕德,邹宇华,邹宗峰,张瑛,周舒冬.广义线性混合效应模型及其应用[J].现代预防医学,2007,34(11):2103-2104. 被引量:19
  • 4Jaffe ES, Harris NL,Stein H, et al. World Health Organi- zation Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue V[M]. (2001).
  • 5Federico M, Bellei M, Marcheselli L, et al. Follicular lym- phoma international prognostic index 2.a new prognostic index for follicular lymphoma developed by the interna- tional follicular lymph'oma prognostic factor project [J]. J Clin Oncol, 2009,27 (27) : 4555-4562.
  • 6Kikuchia A, Nakamurab N, Kuze T,et al. Characterization of de novo diffuse large B-cell lymphoma with a translo- cation of c-myc and immunoglobulin genes [J]. Leuk Res, 2008,32(8) : 1176-1182.
  • 7Akkaya B,Salim O,Akkaya H,et al. C-MYC and BCL2 translocation frequency in diffuse large B-cell lym- phomas:a study of 97 patients [J]. Indian J Pathol Mi- crobiol, 2016,59 ( 1 ) : 41-46.
  • 8Kramer MHH, Hermans J, Wijburg E, et al. Clinical rele- vance of Bcl-2, Bcl-6 and MYC rearrangements in dif- fuse large B-cell lymphoma [J]. Blood, 1998,92(9) :3152- 3162.
  • 9Huang JZ, Sanger WG, Greiner TG, et al. e t ( 14; 18) de- fines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile [J]. Blood, 2002,99 (7) : 2285-2290.
  • 10Perry AM,Alvarado-Bernal Y,Laurini JA,et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with ritux- imab. [J]. Br J Haematol, 2014,165(3) :382-391.

引证文献12

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部